Breaking News Instant updates and real-time market news.

CETX

Cemtrex

$1.40 /

-0.06 (-4.11%)

16:32
02/21/20
02/21
16:32
02/21/20
16:32

Cemtrex discloses 500% increase in new orders for VR/AR development

Cemtrex announced that it has received over $300,000 in new orders for the development of virtual reality, or VR, and augmented reality, or AR, applications, representing a 500% increase in the current quarter to date from the prior year. The orders were from 3 different customers and the company expects to execute these orders over the next five months. The company expects to close an additional $300,000 in new orders for virtual and augmented reality application development in the current quarter with multiple new customers based on the current sales pipeline for a total of $600,000 in FY Q2. The expected $600,000 in orders represents a 1000% percent increase in orders for VR and AR app development services compared to the same period a year ago. The company anticipates that demand for VR and AR app development services will continue to increase in the coming quarters and will be a key source of growth for the company.

TODAY'S FREE FLY STORIES

General news
FX Action: USD-CAD retraced most of Friday's gain » 04:10
04/06/20
04/06
04:10
04/06/20
04:10

FX Action: USD-CAD…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
FX Update: Commodity currencies have rallied » 03:30
04/06/20
04/06
03:30
04/06/20
03:30

FX Update: Commodity…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
Asian Market Update: » 03:05
04/06/20
04/06
03:05
04/06/20
03:05

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Downgrade
Tsingtao Brewery downgraded to Neutral from Buy at Goldman Sachs » 21:42
04/05/20
04/05
21:42
04/05/20
21:42
TSGTF

Tsingtao Brewery

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Lincoln Kong downgraded Tsingtao Brewery to Neutral from Buy with a HK$45.10 price target. More intense competition in the premium beer segment as well as high near-term promotion pressure in the channel make for a challenged position for the company, Kong tells investors in a research note. The analyst sees limited upside catalysts in the near term for the stock.

Downgrade
UBS downgrades Northern Trust to Sell on downside earnings risk » 21:40
04/05/20
04/05
21:40
04/05/20
21:40
NTRS

Northern Trust

$77.18 /

+0.26 (+0.34%)

, BK

BNY Mellon

$33.69 /

+ (+0.00%)

UBS analyst Brennan…

UBS analyst Brennan Hawken downgraded Northern Trust (NTRS) to Sell from Neutral with a price target of $65, down from $105. The bank is more at risk to negative earnings revisions than peers, says the analyst, whose updated 2021 estimates are 33% below consensus. However, Northern Trust's valuation premium to peers is several standard deviation above its long-term average, Hawken tells investors in a research note. As such, the company "far more vulnerable to downside," contends Hawken. Among the trust banks, the analyst continues to prefer BNY Mellon (BK).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Raytheon Technologies reinstated with a Sector Perform at RBC Capital » 21:35
04/05/20
04/05
21:35
04/05/20
21:35
RTX

Raytheon Technologies

$49.87 /

-36.17 (-42.04%)

RBC Capital analyst Deane…

RBC Capital analyst Deane Dray initiated coverage of Raytheon Technologies with a Sector Perform rating and $53 price target. The company should be "partly insulated" from the unfolding coronavirus fallout, but its valuation is not compelling enough to outweigh the uncertainty, Dray tells investors in a research note.

ShowHide Related Items >><<
Downgrade
Cemex downgraded to Neutral on 2020 EBITDA decline at JPMorgan » 21:33
04/05/20
04/05
21:33
04/05/20
21:33
CX

Cemex

$1.73 /

-0.145 (-7.73%)

JPMorgan analyst Adrian…

JPMorgan analyst Adrian Huerta downgraded Cemex to Neutral from Overweight without a price target. The year does not look good for Cemex, says the analyst, who expects the company's EBITDA to decline 30% versus last year. Huerta believes the timing of a potential recovery will take a couple of months to fully understand and that Cemex's leverage could year six times by the end of 2020. Despite the stock's 50% drop year-to-date, the valuation looks unattractive on an enterprise value to EBITDA basis, Huerta tells investors in a research note.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Gannett downgraded to Sell from Buy at Citi » 21:29
04/05/20
04/05
21:29
04/05/20
21:29
GCI

Gannett

$0.81 /

-0.155 (-16.14%)

Citi analyst Jason…

Citi analyst Jason Bazinet double downgraded Gannett to Sell from Neutral with a price target of 50c, down from $5. With the likely depth of the advertising downturn, Gannett may face "significant" EBITDA contraction, Bazinet tells investors in a research note. When coupled with the company's elevated leverage and limited liquidity, the risk of diminishing equity value is material, adds the analyst.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Northern Trust downgraded to Sell from Neutral at UBS » 21:13
04/05/20
04/05
21:13
04/05/20
21:13
NTRS

Northern Trust

$77.18 /

+0.26 (+0.34%)

UBS analyst Brennan…

UBS analyst Brennan Hawken downgraded Northern Trust to Sell from Neutral with a price target of $65, down from $105.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Cemex downgraded to Neutral from Overweight at JPMorgan » 21:11
04/05/20
04/05
21:11
04/05/20
21:11
CX

Cemex

$1.73 /

-0.145 (-7.73%)

JPMorgan analyst Adrian…

JPMorgan analyst Adrian Huerta downgraded Cemex to Neutral from Overweight.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
TechnipFMC upgraded to Outperform from Underperform at Bernstein » 21:09
04/05/20
04/05
21:09
04/05/20
21:09
FTI

TechnipFMC

$7.20 /

-0.335 (-4.45%)

Bernstein analyst…

Bernstein analyst Nicholas Green upgraded TechnipFMC to Outperform from Underperform with a price target of $14.10, down from $16.30.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Subsea 7 SA upgraded to Outperform from Market Perform at Bernstein » 21:08
04/05/20
04/05
21:08
04/05/20
21:08
SUBC

Subsea 7 SA

$0.00 /

+ (+0.00%)

Bernstein analyst…

Bernstein analyst Nicholas Green upgraded Subsea 7 SA to Outperform from Market Perform with a price target of NOK 100, down from NOK 102.

Upgrade
Schlumberger upgraded to Outperform from Underperform at Bernstein » 21:07
04/05/20
04/05
21:07
04/05/20
21:07
SLB

Schlumberger

$14.30 /

+0.44 (+3.17%)

Bernstein analyst…

Bernstein analyst Nicholas Green upgraded Schlumberger to Outperform from Underperform with a price target of $17.90, down from $26.90.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Patterson-UTI upgraded to Market Perform from Underperform at Bernstein » 21:07
04/05/20
04/05
21:07
04/05/20
21:07
PTEN

Patterson-UTI

$1.70 /

-0.175 (-9.33%)

Bernstein analyst…

Bernstein analyst Nicholas Green upgraded Patterson-UTI to Market Perform from Underperform with a price target of $2.10, down from $6.90.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Oceaneering upgraded to Market Perform from Underperform at Bernstein » 21:06
04/05/20
04/05
21:06
04/05/20
21:06
OII

Oceaneering

$2.82 /

-0.21 (-6.93%)

Bernstein analyst…

Bernstein analyst Nicholas Green upgraded Oceaneering to Market Perform from Underperform with a price target of $4, down from $9.90.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
National Oilwell upgraded to Outperform from Market Perform at Bernstein » 21:06
04/05/20
04/05
21:06
04/05/20
21:06
NOV

National Oilwell

$9.85 /

-0.25 (-2.48%)

Bernstein analyst…

Bernstein analyst Nicholas Green upgraded National Oilwell to Outperform from Market Perform with a price target of $14.40, down from $22.30.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Helmerich & Payne upgraded to Outperform from Market Perform at Bernstein » 21:05
04/05/20
04/05
21:05
04/05/20
21:05
HP

Helmerich & Payne

$15.44 /

-0.905 (-5.54%)

Bernstein analyst…

Bernstein analyst Nicholas Green upgraded Helmerich & Payne to Outperform from Market Perform with a price target of $21.20, down from $43.30.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Halliburton upgraded to Market Perform from Underperform at Bernstein » 21:05
04/05/20
04/05
21:05
04/05/20
21:05
HAL

Halliburton

$7.61 /

+0.105 (+1.40%)

Bernstein analyst…

Bernstein analyst Nicholas Green upgraded Halliburton to Market Perform from Underperform with a price target of $6.70, down from $17.60.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Baker Hughes upgraded to Outperform from Underperform at Bernstein » 21:05
04/05/20
04/05
21:05
04/05/20
21:05
BKR

Baker Hughes

$10.38 /

+0.025 (+0.24%)

Bernstein analyst…

Bernstein analyst Nicholas Green upgraded Baker Hughes to Outperform from Underperform with a price target of $15.30, down from $20.40.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Infineon upgraded to Buy from Hold at Societe Generale » 20:56
04/05/20
04/05
20:56
04/05/20
20:56
IFNNY

Infineon

$0.00 /

+ (+0.00%)

Societe Generale analyst…

Societe Generale analyst Alexander Peterc upgraded Infineon to Buy from Hold with a price target of EUR 14.50, down from EUR 20. The analyst believes valuation is "too low" and Infineon's late-cycle businesses look resilient, with certain areas seeing good demand. Peterc expects a solid recovery and margin restoration in 2021, after a difficult 2020, and thinks shares have fallen too far.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Cemex downgraded to Neutral from Outperform at Credit Suisse » 20:49
04/05/20
04/05
20:49
04/05/20
20:49
CX

Cemex

$1.73 /

-0.145 (-7.73%)

Credit Suisse downgraded…

Credit Suisse downgraded Cemex to Neutral from Outperform.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Designer Brands downgraded to Neutral from Positive at Susquehanna » 20:48
04/05/20
04/05
20:48
04/05/20
20:48
DBI

Designer Brands

$3.81 /

-0.29 (-7.07%)

Susquehanna analyst Sam…

Susquehanna analyst Sam Poser downgraded Designer Brands to Neutral from Positive with a $4 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Steven Madden downgraded to Neutral from Positive at Susquehanna » 20:48
04/05/20
04/05
20:48
04/05/20
20:48
SHOO

Steven Madden

$20.51 /

-0.48 (-2.29%)

Susquehanna analyst Sam…

Susquehanna analyst Sam Poser downgraded Steven Madden to Neutral from Positive with a $22 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: Top five weekend stock stories » 20:09
04/05/20
04/05
20:09
04/05/20
20:09
GILD

Gilead

$78.22 /

+1.255 (+1.63%)

, BA

Boeing

$124.59 /

+1.38 (+1.12%)

, FB

Facebook

$154.19 /

-3.92 (-2.48%)

, TWTR

Twitter

$23.08 /

+0.07 (+0.30%)

, GOOG

Alphabet

$1,097.93 /

-25.87 (-2.30%)

, GOOGL

Alphabet Class A

$1,092.51 /

-24.78 (-2.22%)

, UAL

United Airlines

$22.89 /

-0.53 (-2.26%)

, CMCSA

Comcast

$33.94 /

-0.43 (-1.25%)

, CMCSK

Comcast

$0.00 /

+ (+0.00%)

, T

AT&T

$27.46 /

-1.305 (-4.54%)

, VZ

Verizon

$54.72 /

-0.52 (-0.94%)

, ABT

Abbott

$79.50 /

+0.075 (+0.09%)

, CVX

Chevron

$75.15 /

-1.07 (-1.40%)

, HRL

Hormel Foods

$48.37 /

+0.72 (+1.51%)

, JNJ

Johnson & Johnson

$134.13 /

+1.05 (+0.79%)

, KMB

Kimberly-Clark

$130.02 /

+0.58 (+0.45%)

, MDT

Medtronic

$86.17 /

+0.02 (+0.02%)

, PG

Procter & Gamble

$115.10 /

+0.68 (+0.59%)

, TROW

T. Rowe Price

$95.02 /

-2.13 (-2.19%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Gilead Sciences (GILD) said it is donating 1.5M doses of its experimental anti-coronavirus drug remdesivir, which could treat 140,000 patients. In an open letter, Chairman and CEO Daniel O'Day said that the drug will be offered for compassionate use, expanded access and clinical trials, and will treat patients with severe symptoms. "Our existing supply, including finished product ready for distribution as well as investigational medicine in the final stages of production, amounts to 1.5 million individual doses. Depending on the optimal duration of treatment, which is something we are studying in clinical trials, this supply could equate to well over 140,000 treatment courses for patients. [...] Gilead is providing the entirety of this existing supply at no cost, to treat patients with the most severe symptoms of COVID-19. The 1.5 million individual doses are available for compassionate use, expanded access and clinical trials and will be donated for broader distribution following any potential future regulatory authorizations. These doses are for treating patients with severe symptoms, through daily intravenous infusions in a hospital setting. Having a potential treatment in our hands comes with significant responsibility." 2. Boeing (BA) announced that it is extending the temporary suspension of production operations at all Puget Sound area and Moses Lake sites until further notice. "These actions are being taken in light of the company's continuing focus on the health and safety of employees, current assessment of the spread of COVID-19 in Washington state, the reliability of the supply chain and additional recommendations from government health authorities," the plane maker said in a statement Sunday night. 3. Across the media landscape, advertising is disappearing, one more casualty of the global economic shutdown, and new technology won't be a savior as this is an equal-opportunity problem across print, TV, digital, radio, and outdoor advertising, Eric Savitz wrote in this week's edition of Barron's. Even the most prominent ad buyers lack reasons, and often the means, to buy ads, the author notes, while many of the small and medium-size businesses that buy online ads are struggling to stay solvent. Both Facebook (FB) and Twitter (TWTR) have already warned that they will take a hit from the downturn, and Alphabet's Google (GOOGL) no doubt is seeing the same effects, but so far hasn't discussed the matter, the publication adds. 4. United Airlines (UAL) is cutting nearly 90% of its New York-area flying, as public health officials predicted that the city will reach the peak of its novel coronavirus outbreak in the coming days, The Wall Street Journal's Alison Sider reported. The airline said the reductions set to remain in place for at least three weeks will mean substantially fewer employees will need to show up each day, though workers will continue to receive pay and benefits, the author noted. 5. Comcast (CMCSA), AT&T (T), Verizon (VZ), Abbott Laboratories (ABT), Chevron (CVX), Hormel Foods (HRL), Johnson & Johnson (JNJ), Kimberly-Clark (KMB), Medtronic (MDT), Procter & Gamble (PG), and T. Rowe Price (TROW) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Konecranes upgraded to Neutral from Sell at Goldman Sachs » 20:06
04/05/20
04/05
20:06
04/05/20
20:06
KNCRF

Konecranes

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Daniela Costa upgraded Konecranes to Neutral from Sell with an EUR 18 price target. The analyst cites valuation for the upgrade following the stock's recent underperformance and believes the company's liquidity is better than what's currently priced in.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.